RELAPSING-REMITTING MULTIPLE SCLEROSIS
Clinical trials for RELAPSING-REMITTING MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new RELAPSING-REMITTING MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radical stem cell 'Reset' tested as last hope for tough MS cases
Disease control Recruiting nowThis study is testing whether a stem cell transplant can better control multiple sclerosis (MS) than the best available drugs in people whose MS stays active despite treatment. It will involve 156 adults whose MS has flared up despite taking strong medications. Participants will …
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Tiny neck implant aims to repair MS nerve damage
Disease control Recruiting nowThis study is testing whether a small device implanted in the neck can help repair the protective coating around nerves (myelin) in people with relapsing-remitting multiple sclerosis (RRMS). The device delivers mild electrical stimulation to the vagus nerve. Up to 60 participants…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS
Phase: NA • Sponsor: SetPoint Medical Corporation • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Cheaper MS drug put to the test in major Head-to-Head trial
Disease control Recruiting nowThis study aims to find out if an older, less expensive drug called rituximab works just as well as a newer, much more expensive drug called ocrelizumab for controlling relapsing multiple sclerosis (MS). About 386 adults with active relapsing MS will be randomly assigned to recei…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Rennes University Hospital • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Cancer drug repurposed in bold bid to tame MS
Disease control Recruiting nowThis early-stage study is checking if a drug called ixazomib, used for a type of blood cancer, is safe for people with multiple sclerosis (MS). The goal is to see if it can reduce harmful antibodies linked to MS in the fluid around the brain and spine. About 72 participants with …
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS
Phase: PHASE1 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Feb 24, 2026 14:06 UTC
-
Can changing what you eat ease the burden of MS?
Symptom relief Recruiting nowThis study is testing whether two specific diet plans, followed by a period of calorie restriction for weight loss, can improve daily life for people with multiple sclerosis. One hundred adults with MS will follow either a low-glycemic or standard diet for 32 weeks, with free gro…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Mar 11, 2026 14:53 UTC
-
New digital tool aims to transform MS monitoring
Knowledge-focused Recruiting nowThis study is testing a new digital platform designed to help doctors better monitor and manage people with relapsing-remitting multiple sclerosis (MS). The platform includes an app for patients to track their health and a system for doctors to analyze brain scans using artificia…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
Scientists probe the Long-Lasting mystery of MS drugs
Knowledge-focused Recruiting nowThis study aims to understand why certain effective MS therapies continue to work long after treatment. Researchers will closely follow 100 people with relapsing-remitting MS who are taking specific B-cell targeting drugs. They will collect detailed health data and blood samples …
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS
Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:08 UTC